p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.

Abstract

BACKGROUND:

Despite advances in early diagnosis and treatment of cancer patients, metastasis remains the major cause of mortality. TP53 is one of the most frequently mutated genes in human cancer, and these alterations can occur during the early stages of oncogenesis or as later events as tumors progress to more aggressive forms. Previous studies have suggested that p53 plays a role in cellular pathways that govern metastasis. To investigate how p53 deficiency contributes to late-stage tumor growth and metastasis, we developed paired isogenic patient-derived xenograft (PDX) models of triple-negative breast cancer (TNBC) differing only in p53 status for longitudinal analysis.

METHODS:

Patient-derived isogenic human tumor lines differing only in p53 status were implanted into mouse mammary glands. Tumor growth and metastasis were monitored with bioluminescence imaging, and circulating tumor cells (CTCs) were quantified by flow cytometry. RNA-Seq was performed on p53-deficient and p53 wild-type tumors, and functional validation of a lead candidate gene was performed in vivo.

RESULTS:

Isogenic p53 wild-type and p53-deficient tumors metastasized out of mammary glands and colonized distant sites with similar frequency. However, p53-deficient tumors metastasized earlier than p53 wild-type tumors and grew faster in both primary and metastatic sites as a result of increased proliferation and decreased apoptosis. In addition, greater numbers of CTCs were detected in the blood of mice engrafted with p53-deficient tumors. However, when normalized to tumor mass, the number of CTCs isolated from mice bearing parental and p53-deficient tumors was not significantly different. Gene expression profiling followed by functional validation identified B cell translocation gene 2 (BTG2), a downstream effector of p53, as a negative regulator of tumor growth both at primary and metastatic sites. BTG2 expression status correlated with survival of TNBC patients.

CONCLUSIONS:

Using paired isogenic PDX-derived metastatic TNBC cells, loss of p53 promoted tumor growth and consequently increased tumor cell shedding into the blood, thus enhancing metastasis. Loss of BTG2 expression in p53-deficient tumors contributed to this metastatic potential by enhancing tumor growth in primary and metastatic sites. Furthermore, clinical data support conclusions generated from PDX models and indicate that BTG2 expression is a candidate prognostic biomarker for TNBC.

• Authors: Emily Powell, Jiansu Shao, Yuan Yuan, Hsiang-Chun Chen, Shirong Cai, Gloria V Echeverria, Nipun Mistry, Keith F Decker, Christopher Schlosberg, Kim-Anh Do, John R Edwards, Han Liang, David Piwnica-Worms, Helen Piwnica-Worms
• Journal: Breast cancer research : BCR (Breast Cancer Res) Vol. 18 Issue 1 Pg. 13 (Jan 27 2016) ISSN: 1465-542X [Electronic] England
• PMID: 26818199 (Publication Type: Journal Article)

Chemical References

• Immediate-Early Proteins
• TP53 protein, human
• Tumor Suppressor Protein p53
• Tumor Suppressor Proteins
• BTG2 protein, human

Topics

• Animals
• Apoptosis (genetics)
• Cell Line, Tumor
• Cell Proliferation (genetics)
• Disease Models, Animal
• Female
• Humans
• Immediate-Early Proteins (biosynthesis, genetics)
• Mice
• Neoplasm Metastasis
• Neoplastic Cells, Circulating (pathology)
• Triple Negative Breast Neoplasms (genetics, pathology)
• Tumor Suppressor Protein p53 (genetics)
• Tumor Suppressor Proteins (biosynthesis, genetics)
• Xenograft Model Antitumor Assays